Company: SHPH
Filing Date: 2025-04-21
Form Type: DEFR14A
Source: 0001641172-25-005474
Chunk: 6

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-04-21
Form: DEFR14A
Chunk 6
---

 equivalents will not be paid unless vesting and performance conditions for Restricted Stock Units (RSUs), to which such rights attach, 
 are met.                                                                                                                               |
| ● | We                                                                                                                                     
 do not provide significant perquisites to our named executive officers.                                                                |

Board of Directors and Corporate Governance

Below is biographical information about each of our directors:

Anatoly Dritschilo, M.D.Dr. Dritschilo is a co-founder of the Company and has served as Chief Executive Officer and Chairman of the Board of Directors since the Company’s formation in December 2012. In March 2025, Dr. Dritschilo assumed the role of Chief Scientific Officer, with his role focused on overseeing clinical trials and scientific development at the Company, while remaining in the position of Chairman of the Board of Directors. Dr. Dritschilo is a radiation oncologist by training and has held multiple leadership positions in health care. At Georgetown University Medical School in Washington, D.C., he served principally as Department Chair from 1980 to 2022; Chief of Radiation Oncology at MedStar-Georgetown University Hospital from 2005 to 2022; Medical Director of Georgetown University Hospital from 1994 to 1997; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005 to 2007. He has also served on the boards of directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital, and the MedStar Health Research Institute. Previously, he was a founding director of Oncomed, Inc. and a member of the board of directors of Neopharm, Inc. His 250+ scientific publications and 20+ issued patents have earned him election as a Fellow of the National Academy of Inventors. Dr. Dritschilo holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania, a Master of Science degree from the New Jersey Institute of Technology, a medical degree from the College of Medicine of New Jersey (Rutgers) and residency training from the Harvard Joint Center for Radiation Therapy. His qualifications support his service as our Chief Scientific Officer and Chairman of the Board of Directors.

| 4 |

Steven Richards.Mr. Richards was appointed to be a member of our Board of Directors in 2019. He is Chief Executive Officer and Founder of Endurance Media, a media finance company based in Santa Monica, California, that launched in 2014 with a strategic alliance with eOne Entertainment and a mandate to produce